Research Spotlight

Finding patterns of etanercept use in patients with Juvenile Idiopathic Arthritis (JIA)

Etanercept has been used to treat many types of JIA for more than 20 years. This study sought to discover patterns of etanercept use among 2,032 patients within the Registry's JIA cohort.

Investigator and Registry Scientific Director Timothy Beukelman, MD, MSCE, shared how this helps patients and families. "They may be comforted to know," he said, "that quick initiation of etanercept has become a standard approach to treatment."

Key findings: etanercept was most often prescribed alongside methotrexate, but given after a short time on methotrexate. Additional findings include:

- More than one-half of patients treated with etanercept started it within 6 months of JIA diagnosis (median 4.3 months)
- Patients with more severe symptoms started etanercept sooner
- Doctors were most likely to treat patients enthesitis-related arthritis (ERA) with etanercept only
- Patients with persistent OligoJIA were most likely to stop methotrexate treatment around the same time as starting etanercept
- Doctors used etanercept as a long-term treatment option

This study was supported by Amgen.

Read more here.

DATES AND DEADLINES

September

- 9/19-21: PReS 2021
- 9/24: Nominations due, DEI Committee elections (Rd. 1)
- 9/28: Late-breaking abstracts due noon ET, ACR Convergence

October

- 10/1: RFA's due, Fall Grant Cycle
- 10/14-24: Vote! DEI Committee (Rd. 1)
- 10/28: Nominations due, DEI Committee elections (Rd. 2)

Applications for the fall grant cycle are being accepted until Oct. 1.
NEW! CARRA Registry Systemic JIA-Associated Lung Disease Cohort Study

In July, initial patients were enrolled and biosamples collected in the first international, prospective study of SJIA-LD. The study is funded by a CARRA Large Grant, and seeks to increase SJIA-LD patients in the Registry, as well as collect information and biosamples. Download the eligibility criteria here.

If your CARRA site currently follows patients with SJIA-LD, contact Grant Schulert or Yuki Kimura to activate your site.

Last Chance!
Fall Grant Cycle
RFA’s due Oct. 1

Oct. 1 is the last day to apply for large and small grants in this year’s fall grant cycle.

Applications are being accepted from Sept. 1 to Oct. 1. These include:

- **Large Grant** ($100,000)
- **Small Grant** ($50,000)
- **Health Equity Research Grant** ($150,000)
- **ABC Grant** ($50,000)

Don’t miss out on these significant funding opportunities. Send your applications in today!

Current Registry Enrollment

11,710 patients enrolled
797 biosamples collected

Since our report this past August, you’ve helped steadily increase the number of patients and biosamples available for study.

Thank you for your efforts!